시스타티오닌 베타-합성 효소 결핍증(COMPOSE)으로 인한 호모시스틴뇨증 환자를 위한 효소 요법으로서의 페그티바티나아제
안전성, 내약성, 약동학, 약력학 및 시스타티오닌 베타-합성 효소 결핍 호모시스틴뇨증 환자에게 피하 투여된 Pegtibatinase(TVT-058)의 임상 결과에 대한 효과를 평가하기 위한 이중 맹검, 무작위, 위약 대조, 1/2상 연구 (구성하다)
CBS(Cystathionine Beta-Synthase) 결핍에 의해 유발되는 호모시스틴뇨증은 혈장, 조직 및 소변에서 호모시스테인(Hcy)의 과잉을 특징으로 하는 희귀한 상염색체 열성 대사 상태입니다. 이는 CBS 효소의 활성이 감소하거나 없기 때문에 발생하며 고전적 호모시스틴뇨증으로도 알려져 있습니다. 호모시스틴뇨증과 관련된 증상은 환자마다 심각도와 발병 시간이 다양합니다. 영향을 받은 일부 개인은 장애의 경미한 징후를 보일 수 있습니다. 다른 사람들은 잠재적으로 생명을 위협하는 합병증을 포함하여 다중 전신 관련이 있을 수 있습니다. 호모시스틴뇨증은 신체의 다양한 기관계에 영향을 미칠 수 있습니다. 가장 일반적으로 관련된 네 가지는 눈, 중추 신경계, 골격 및 혈관계입니다.
호모시스틴뇨증 환자의 치료에 대한 현재의 접근법은 매우 제한적인 식이요법과 식이 보충제의 사용을 포함합니다. 이 식단에 대한 평생 순응도는 좋지 않습니다. 페그티바티나제(TVT-058)는 천연 인간 CBS(hCBS) 효소의 변형된 버전을 사용하는 새로운 치료 접근법을 나타냅니다. 치료의 목표는 CBS 효소를 순환계로 도입하여 Hcy 수준을 낮추고 시스타티오닌(Cth) 및 시스테인(Cys) 수준을 증가시키는 것입니다.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
Primary Objective - Cohorts 1-6
Researchers are performing this study to learn if pegtibatinase is safe and tolerable (how it makes participants feel).
Researchers will use medical examination, blood tests, and urine tests to measure side effects (unwanted health problems that may or may not be related to the study treatment), changes in laboratory tests and in the electrical activity of the heart (as measured by electrocardiogram or "ECG"), and if the body makes antibodies to fight against pegtibatinase. Antibodies are proteins that the body makes that may stop pegtibatinase from working or may cause side effects.
Secondary Objectives - Cohorts 1-6
Researchers also want to learn about:
- What are the levels of pegtibatinase in the body after single and repeated doses?
- How does pegtibatinase affect levels of certain substances that are produced when the body breaks down and creates homocysteine?
- What are the effects of pegtibatinase on the eyes, bones, mental health, and cognitive function? Researchers will use blood tests, physical examinations, and questionnaires to answer these questions.
Cohort 7 Objectives
Group 7 is open to children aged 5 to 11 years old (or "pediatric participants") who meet the requirements for the study.
Researchers are performing this part of the study with Group 7 to learn if pegtibatinase is safe and tolerable (how it makes participants feel) and if it increases antibody levels when it is given to children with HCU.
Researchers will use blood tests and physical examinations to measure side effects that happen during the study, changes in laboratory tests, electrical activity of the heart, antibody levels, vital signs, and the number of pediatric participants that have too high or too low levels of methionine. Researchers will use questionnaires to measure the number of pediatric participants that need more protein in their diet.
Researchers are performing this part of the study with Group 7 because they also want to learn about:
- What are the levels of pegtibatinase in the pediatric participant's body after single and repeated doses?
- How does pegtibatinase affect levels of total homocysteine and methionine in the pediatric participant's body? Researchers will use blood tests to answer these questions.
Study Population and Treatments
This study will include children and adults from 5 to 65 years old with HCU. Participants in Groups 1 to 6 were aged 12 to 65 years old, and Group 7 participants will be aged 5 to 11 years old. Participants in the study will take their standard of care treatment.
Groups 1 to 6 have completed this study already. For these groups, 24 participants aged 12 to 65 years old who met the requirements of the study were split into 1 of the 6 groups. For each group, 3 participants were chosen to take pegtibatinase for every 1 participant chosen to take an injection that does not have any medicine in it (or "placebo"). Participants were assigned to pegtibatinase or placebo by chance, like the flip of a coin. This is called "randomization". Neither the researchers nor the participants knew which treatment they were getting until the study was completed. This is known as a "double-blind" approach.
Group 7 is open and will be conducted globally. It will include 10 to 15 pediatric participants aged 5 to 11 years old who meet the requirements of the study. All participants in this group will receive pegtibatinase. All participants will know that this is the treatment that they receive. This is called an "open label" approach. The treatment period will be separated into 3 parts: Part A, Part B, and Part C. Each part will test a different dose of pegtibatinase. After each part, pediatric participants who meet specific requirements will move to the next part. If the pediatric participants do not meet specific requirements to move to the next part, they will have the option to join the ENSEMBLE study (NCT06431893) and continue taking that same dose.
Pegtibatinase or placebo will be given as an injection under the skin (or "subcutaneous injection"). Doses for each group are shown below.
- Group 1: 0.33 mg/kg pegtibatinase or placebo 1 time a week.
- Group 2: 0.66 mg/kg pegtibatinase or placebo 1 time a week.
- Group 3: 1.0 mg/kg pegtibatinase or placebo 1 time a week.
- Group 4: 1.0 mg/kg pegtibatinase or placebo 2 times a week.
- Group 5: 1.5 mg/kg pegtibatinase or placebo 2 times a week.
- Group 6: 2.5 mg/kg pegtibatinase or placebo 2 times a week.
- Group 7:
- Part A: 1.0 mg/kg pegtibatinase 2 times a week for 8 weeks;
- Part B: 1.5 mg/kg pegtibatinase 2 times a week for 8 weeks;
- Part C: 2.5 mg/kg pegtibatinase 2 times a week for 4 weeks.
Study Duration and Visits
Participants in Groups 1 to 6 were in the study for up to 158 weeks, including the screening period of up to 8 weeks, a double-blind treatment period of up to 12 weeks, and an extension period of up to 138 weeks. A continuation study called ENSEMBLE was available to participants. Participants were offered to join the ENSEMBLE study before they finished the extension period of the COMPOSE study.
Pediatric participants in Group 7 may be in the study for up to 42 weeks, including the screening period of up to 10 weeks, open-label treatment period of up to 20 weeks, and up to 12 weeks of additional treatment at the same dose if the ENSEMBLE study is not yet open.
If participants in Group 7 meet all the requirements of the study, they will have up to 53 visits to a study center or at home. If the ENSEMBLE study is not yet open at their site, they can have up to 23 more visits to continue treatment.
These visits can include:
- Blood and urine tests
- Physical examinations
- Questionnaires
- Injections
- Questions about how they are feeling or any problems they are having
Safety / Adverse Events
Researchers will keep track of any medical problems that a participant has during a study (or "adverse event"). All participants in this study will have regular laboratory tests, health checkups, and site visits to watch for health risks and measure safety.
Benefit-Risk Conclusion Researchers have worked to reduce risks to participants in this study. They believe the risks of taking pegtibatinase in this study are justified by the potential benefits that they think pegtibatinase may have for people with HCU.
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 2 단계
- 1단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Travere Call Center
- 전화번호: 1-877-659-5518
- 이메일: medinfo@travere.com
연구 장소
-
-
Colorado
-
Aurora, Colorado, 미국, 80045
- 완전한
- Travere Investigational Site
-
-
Florida
-
Miami, Florida, 미국, 33136
- 완전한
- Travere Investigational Site
-
-
Illinois
-
Chicago, Illinois, 미국, 60611
- 아직 모집하지 않음
- Ann & Robert H. Lurie Children's Hospital of Chicago
-
-
Indiana
-
Indianapolis, Indiana, 미국, 46202
- 완전한
- Travere Investigational Site
-
-
Maine
-
Portland, Maine, 미국, 04102
- 완전한
- Travere Investigational Site
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02115
- 완전한
- Travere Investigational Site
-
-
New York
-
New York, New York, 미국, 10029
- 아직 모집하지 않음
- The Mount Sinai Hospital
-
New York, New York, 미국, 10029
- 완전한
- Travere Investigational Site
-
-
North Carolina
-
Morrisville, North Carolina, 미국, 27560
- 모병
- Science 37 - Virtual Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, 미국, 19104
- 완전한
- Travere Investigational Site
-
-
-
-
-
Doha, 카타르
- 아직 모집하지 않음
- Sidra Medicine
-
-
-
-
-
Paris, 프랑스, 75015
- 아직 모집하지 않음
- Hospital Necker-Enfants Malades, Neurologie Pediatrique
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
설명
포함 기준:
- 유전적 확인 및 혈장 tHcy ≥50 micromoles 및 이전 tHcy 수준 ≥80 micromoles의 문서화를 기반으로 호모시스틴뇨증 진단 확인
- 서면으로 서명된 정보에 입각한 동의를 제공하고 모든 연구 관련 절차를 준수할 의향과 능력이 있습니다.
- 가임 가능성이 있는 생물학적으로 여성으로 태어난 피험자는 스크리닝 시 임신 검사 결과가 음성이어야 하고 연구 중에 추가 임신 검사를 받을 의향이 있어야 합니다. 생물학적으로 남성으로 태어나 여성으로 식별되고 가임 능력이 없는 피험자는 임신 테스트를 받을 필요가 없습니다.
- 가임 가능성이 있는 성적으로 활동적인 대상자 또는 가임 가능성이 있는 파트너가 있는 대상자는 연구 기간 동안 및 연구 종료 후 4주 동안 허용 가능한 피임 방법을 기꺼이 사용해야 합니다.
- 공부하는 동안 큰 변화 없이 안정적인 식단을 유지하고 일일 식단 일기를 작성하고자 합니다.
제외 기준:
- 페그티바티나아제에 대한 이전 노출 및/또는 페그티바티나아제 투여를 포함하는 임상 시험에의 이전 참여
- 스크리닝 전 30일 이내 또는 연구 중에 임의의 연구 제품 또는 연구 의료 기기 사용
- 스크리닝 전 3개월 내 및 연구 참여 기간 동안 메드록시프로게스테론(예: Depo-Provera) 주사를 포함하여 PEG(페그티바티나제 또는 COVID-19 백신 제외)를 포함하는 주사 가능한 약물의 사용 또는 계획된 사용
- PEG 함유 제품 또는 페그티바티나아제 성분에 대해 알려진 과민성
- HIV 항체, B형 간염 표면 항원 또는 C형 간염 항체에 대한 양성 검사
- 장기 이식, 만성 면역억제 요법 또는 약물 남용의 병력
- 연구 기간 동안 언제든지 임신 또는 모유 수유 스크리닝 또는 임신 계획(자신 또는 파트너) 또는 모유 수유
- 조사자의 의견에 따라 연구 참여 또는 안전을 방해할 동시 질병 또는 상태 또는 계획된 주요 수술.
- 연구자의 관점에서 피험자가 치료 순응도가 낮거나 연구를 완료하지 못할 위험이 높은 모든 상태
- 연구 기간 동안 계획된 대수술
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
활성 비교기: Pegtibatinase (Cohort 1-6)
Double-Blind Treatment Cohorts (≥12 to ≤65 years)
|
피하 주사를 위한 페그티바티나제 멸균 용액
다른 이름들:
|
|
위약 비교기: Placebo (Cohort 1-6)
Double-Blind Treatment Cohorts (≥12 to ≤65 years)
|
피하주사용 생리식염수
|
|
실험적: Pegtibatinase (Cohort 7)
Pediatric Open-label Treatment Cohort (≥5 to <12 years)
|
피하 주사를 위한 페그티바티나제 멸균 용액
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Incidence of AEs
기간: • Cohorts 1-6: Through double-blind study completion, approximately 10 months per patient • Cohort 7: First dose through End of Treatment (up to 32 weeks)
|
Incidence of AEs (by type, severity and relationship to study drug)
|
• Cohorts 1-6: Through double-blind study completion, approximately 10 months per patient • Cohort 7: First dose through End of Treatment (up to 32 weeks)
|
|
Anti-pegtibatinase antibodies
기간: • Cohorts 1-6: Through double-blind study completion, approximately 10 months per patient • Cohort 7: First dose through End of Treatment (up to 32 weeks)
|
Presence and levels of anti-pegtibatinase antibodies in plasma as measured by antibody titers
|
• Cohorts 1-6: Through double-blind study completion, approximately 10 months per patient • Cohort 7: First dose through End of Treatment (up to 32 weeks)
|
|
Anti-PEG antibodies
기간: • Cohorts 1-6: Through double-blind study completion, approximately 10 months per patient • Cohort 7: First dose through End of Treatment (up to 32 weeks)
|
Presence and levels of anti-PEG antibodies in plasma as measured by antibody titers
|
• Cohorts 1-6: Through double-blind study completion, approximately 10 months per patient • Cohort 7: First dose through End of Treatment (up to 32 weeks)
|
|
Incidence of hypermethioninemia (Cohort 7 only)
기간: First dose through End of Treatment (up to Week 32)
|
The number and percentage of participants who develop hypermethioninemia during treatment, based on plasma methionine concentrations exceeding the protocol-defined threshold.
Participants meeting the protocol-defined threshold may undergo dietary management or study treatment modifications, as appropriate.
|
First dose through End of Treatment (up to Week 32)
|
|
Incidence of hypomethioninemia (Cohort 7 only)
기간: First dose through End of Treatment (up to Week 32)
|
The number and percentage of participants who develop hypomethioninemia during treatment, based on plasma methionine concentrations below the protocol-defined threshold.
Participants meeting the protocol-defined threshold may receive dietary protein supplementation or study treatment modifications, as appropriate.
|
First dose through End of Treatment (up to Week 32)
|
|
The proportion of participants requiring dietary protein rescue (Cohort 7 only)
기간: First dose through End of Treatment (up to Week 32)
|
The proportion of participants who require initiation of dietary protein supplementation during study treatment to manage protocol-defined low plasma methionine concentrations.
|
First dose through End of Treatment (up to Week 32)
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Changes in pegtibatinase levels
기간: • Cohorts 1-6: Through double-blind study completion, approximately 10 months per patient • Cohort 7: First dose through End of Treatment (up to 32 weeks)
|
Changes in pegtibatinase levels following single and repeat administration at specified timepoints
|
• Cohorts 1-6: Through double-blind study completion, approximately 10 months per patient • Cohort 7: First dose through End of Treatment (up to 32 weeks)
|
|
Changes in Met cycle metabolites levels - tHcy
기간: • Cohorts 1-6: Through double-blind study completion, approximately 10 months per patient • Cohort 7: First dose through End of Treatment (up to 32 weeks)
|
Changes in total homocysteine levels in micromoles
|
• Cohorts 1-6: Through double-blind study completion, approximately 10 months per patient • Cohort 7: First dose through End of Treatment (up to 32 weeks)
|
|
Changes in Met cycle metabolites levels - total Cys (Cohorts 1-6 Only)
기간: Through double-blind study completion, approximately 10 months per patient
|
Changes in total cysteine levels in micromoles
|
Through double-blind study completion, approximately 10 months per patient
|
|
Changes in Met cycle metabolites levels - Me (Cohorts 1-6 Only)
기간: Through double-blind study completion, approximately 10 months per patient
|
Changes in methionine levels in micromoles
|
Through double-blind study completion, approximately 10 months per patient
|
|
Changes in Met cycle metabolites levels - Cth (Cohorts 1-6 Only)
기간: Through double-blind study completion, approximately 10 months per patient
|
Changes in cystathionine levels in micromoles
|
Through double-blind study completion, approximately 10 months per patient
|
|
Changes in Met cycle metabolites levels - Phe (Cohorts 1-6 Only)
기간: Through double-blind study completion, approximately 10 months per patient
|
Changes in phenylalanine levels in micromoles
|
Through double-blind study completion, approximately 10 months per patient
|
|
Descriptive ophthalmology examination findings (Cohorts 1-6 Only)
기간: Through double-blind study completion, approximately 10 months per patient
|
Comprehensive ophthalmological examination (for each eye: visual acuity [myopia, hyperopia, exotropia], slit lamp examination [ectopic lentis, cataracts, corneal abrasion, and uveitis], retinal examination [retinal degeneration, retinal detachment, retinitis pigmentosa, uveitis)]).
Assessment of presence and severity of findings.
|
Through double-blind study completion, approximately 10 months per patient
|
|
Bone densitometry using dual-energy X-ray absorptionmetry (DEXA) scans (Cohorts 1-6 Only)
기간: Through double-blind study completion, approximately 10 months per patient
|
Through double-blind study completion, approximately 10 months per patient
|
|
|
Cognitive assessments using the National Institutes of Health Toolbox Cognition Battery score (Cohorts 1-6 Only)
기간: Through double-blind study completion, approximately 10 months per patient
|
Through double-blind study completion, approximately 10 months per patient
|
|
|
Patient Reported Outcome (PRO): Quality of Life in Neurological Disorders [Neuro-QoL] (Cohorts 1-6 Only)
기간: Through double-blind study completion, approximately 10 months per patient
|
The Quality of Life in Neurological Disorders [Neuro-QoL] includes Anxiety Short Form, Depression Short Form, Satisfaction with Social Roles Short Form, Cognition Function Short Form for 18+ years of age; Anxiety Short Form, Depression Short Form, Social Relations - Interaction with Peers Short Form, and Cognitive Function Short Form for Ages 12 to 17 years old
|
Through double-blind study completion, approximately 10 months per patient
|
|
Patient Reported Outcome (PRO): Quality of Life by 36-Item Short Form Survey [SF-36] (Cohorts 1-6 Only)
기간: Through double-blind study completion, approximately 10 months per patient
|
Through double-blind study completion, approximately 10 months per patient
|
|
|
Patient Reported Outcome (PRO): Quality of Life by EuroQol 5-Dimentional Instrument [EQ 5D] (Cohorts 1-6 Only)
기간: Through double-blind study completion, approximately 10 months per patient
|
Through double-blind study completion, approximately 10 months per patient
|
공동 작업자 및 조사자
수사관
수사관
- 연구 책임자: Michael Imperiale, MD, Travere Therapeutics, Inc.
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- CBS-HCY-CT-01
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
IPD 공유 기간
IPD 공유 액세스 기준
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .